Cochrane · systematic review · CD007744
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
Miao, XP, Li, JS, Ouyang, Q, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Etoricoxib versus placebo for treatment of rheumatological manifestations of inflammatory bowel disease
Population: patients with active or quiescent IBD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation of IBD Etoricoxib vs placebo | RR 0.88 [0.45, 1.69] | 1 study · 159 participants | Low Downgraded: imprecision |
Celecoxib versus placebo for treatment of rheumatological manifestations of ulcerative colitis
Population: patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation of ulcerative colitis Celecoxib vs placebo | RR 0.7 [0.23, 2.14] | 1 study · 222 participants | Low Downgraded: imprecision |
GI adverse events Celecoxib vs placebo | RR 0.97 [0.46, 2.07] | 1 study · 221 participants | Low Downgraded: imprecision |